POST Online Media Lite Edition


DNAtrix appoints Jeffrey Knapp as chief executive officer

Christian Fernsby |
Houston, Tx., USA - DNAtrix, a developer of oncolytic viruses for cancer therapy, announced that Jeffrey Knapp has been appointed as chief executive officer and to the board of directors.

Mr. Knapp joins DNAtrix with over 30 years of experience in the pharmaceutical industry, including 20 in executive management.

Mr. Knapp has developed and executed strategies supporting clinical development, regulatory approval, and commercial launch of multiple products across a diverse array of therapeutic areas.

Mr. Knapp most recently served as Chief Operating Officer at Aimmune Therapeutics where he was responsible for preparing the company's first asset, AR101, for approval and commercial launch in the United States and Europe as a treatment for children and adolescents with peanut allergies.

Previously, he held several executive and senior management positions in biopharmaceutical companies at similar stages of growth.